Insider · CIK 0001326969

Bedrosian Camille L

Reports to the SEC for 4 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001326969

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-10	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Medical Officer	SSale	−2,081 sh	$33.09	−$68.9K	278,064
2026-09-10	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Medical Officer	SSale	−7,947 sh	$32.21	−$256K	280,145
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	$68.92	−$1.72M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17.5K sh	$64.77	−$1.13M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17.5K sh	$66.71	−$1.17M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17.5K sh	$64.68	−$1.13M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−16.3K sh	$85.00	−$1.39M	5,925
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−12.5K sh	$40.29	−$504K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−5,925 sh	$85.00	−$504K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.4K sh	$52.67	−$545K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−9,730 sh	$49.13	−$478K	0
2026-08-18	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Medical Officer	AAward	+22.8K sh	—	—	288,092
2026-06-18	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+5,925 sh	—	—	22,225
2026-06-18	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,730 sh	—	—	9,730
2026-03-05	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Medical Officer	AAward	+96K sh	—	—	265,285
2026-03-05	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+144K sh	—	—	143,985
2026-03-02	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Medical Officer	SSale	−6,461 sh	$14.58	−$94.2K	169,295
2025-12-01	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Medical Officer	SSale	−6,580 sh	$14.35	−$94.4K	175,756
2025-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Medical Officer	SSale	−12K sh	$14.58	−$176K	182,336
2025-06-24	RYTMRHYTHM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	Director	AAward	+7,037 sh	—	—	7,037
2025-06-24	RYTMRHYTHM PHARMACEUTICALS, INC. · Restricted Stock UnitsA Award	Director	AAward	+4,712 sh	—	—	4,712
2025-06-18	RYTMRHYTHM PHARMACEUTICALS, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−4,000 sh	—	—	0
2025-06-18	RYTMRHYTHM PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+4,000 sh	—	—	7,000
2025-06-11	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+6,900 sh	—	—	16,300
2025-06-11	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.4K sh	—	—	10,350
2025-03-31	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Medical Officer	SSale	−12.4K sh	$3.47	−$43.1K	194,375
2025-03-06	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Medical Officer	AAward	+68.4K sh	—	—	206,800
2025-03-06	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+103K sh	—	—	102,630
2024-12-02	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Medical Officer	SSale	−5,421 sh	$5.54	−$30K	138,380
2024-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Medical Officer	SSale	−11.4K sh	$3.20	−$36.6K	143,801
2024-06-21	RYTMRHYTHM PHARMACEUTICALS, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,000 sh	—	—	0
2024-06-21	RYTMRHYTHM PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+3,000 sh	—	—	3,000
2024-06-18	RYTMRHYTHM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	Director	AAward	+14K sh	—	—	14,000
2024-06-18	RYTMRHYTHM PHARMACEUTICALS, INC. · Restricted Stock UnitsA Award	Director	AAward	+4,000 sh	—	—	4,000
2024-06-07	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+3,400 sh	—	—	9,400
2024-06-07	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2024-04-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+120K sh	—	—	120,000
2024-04-16	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Medical Officer	AAward	+96.9K sh	—	—	155,243
2023-11-27	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Medical Officer	AAward	+58.3K sh	—	—	58,333
2023-11-27	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+163K sh	—	—	162,500
2023-06-21	RYTMRHYTHM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	Director	AAward	+14K sh	—	—	14,000
2023-06-21	RYTMRHYTHM PHARMACEUTICALS, INC. · Restricted Stock UnitsA Award	Director	AAward	+3,000 sh	—	—	3,000
2023-06-16	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+6,000 sh	—	—	6,000
2023-06-16	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2023-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP and Chief Medical Officer	AAward	+2,663 sh	—	—	50,601
2023-03-01	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP and Chief Medical Officer	SSale	−3,881 sh	$45.25	−$176K	46,720
2022-06-17	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2022-06-08	RYTMRHYTHM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-03-01	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	EVP and Chief Medical Officer	AAward	+24.9K sh	—	—	24,900
2022-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP and Chief Medical Officer	AAward	+14K sh	—	—	47,938

Recent filings

Accepted (ET)
Sep 144
Bedrosian Camille L0001193125-26-390510
SEC(opens sec.gov)
Sep 14
Bedrosian Camille L0001628280-26-059900
SEC(opens sec.gov)
Aug 204
Bedrosian Camille L0001193125-26-359676
SEC(opens sec.gov)
Jun 224
Bedrosian Camille L0001628280-26-044712
SEC(opens sec.gov)
Mar 94
Bedrosian Camille L0001193125-26-098436
SEC(opens sec.gov)
Mar 44
Bedrosian Camille L0001193125-26-091440
SEC(opens sec.gov)
Dec 34
Bedrosian Camille L0001193125-25-306818
SEC(opens sec.gov)
Oct 24
Bedrosian Camille L0001193125-25-228339
SEC(opens sec.gov)
Jun 264
Bedrosian Camille L0001104659-25-063080
SEC(opens sec.gov)

Companies

Address

C/O AMYLYX PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 6W

CAMBRIDGE, MA, 02142